Back to dashboard
MedicaidDocumentationHigh impact

Newsletter Vol. 4, No. 26

New Jersey Medicaid·NJ · Pediatrics, Family Medicine, General Practice·Provider Notice
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

New Jersey Medicaid has updated lead screening requirements for children ages 6 months to 6 years, effective immediately. The erythrocyte protoporphyrin (EP) test is no longer acceptable as a screening tool; all screenings must now use blood lead level determination via capillary or venous samples. Providers must perform risk assessments at each visit and obtain blood lead testing based on risk classification.

Action Required

Action needed
Immediately: Providers must cease using EP test for lead screening and transition to blood lead level determination testing for all Medicaid-eligible children ages 6 months to 6 years. Billing team must update encounter forms and clinical workflows to: (1) Ensure providers conduct verbal lead risk assessment using the New Jersey Department of Health's Lead Risk Assessment Questionnaire at each visit for children 6 months to 6 years of age; (2) Implement mandatory blood lead testing at 6-12 months, 2 years, and annually through age 6 for all children regardless of risk status; (3) For high-risk children (any positive response to risk assessment questions), obtain blood lead level test immediately at time of risk determination; (4) Ensure capillary samples with results ≥10 µg/dL are confirmed with venous blood samples. Update billing system to ensure claims reflect appropriate blood lead level determination codes rather than EP test codes. Refer children under 5 years of age to WIC programs for nutritional assessment. Failure to comply will result in Medicaid claim denials and potential compliance violations.